Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Organ transplants
Biotech
Triple phase 3 disaster sends AlloVir shares plunging 64%
AlloVir’s ambitions, like its share price, have shrunk significantly as the biotech abandons three late-stage trials of its lead asset
James Waldron
Dec 22, 2023 9:00am
Paragonix launches nationwide organ transplant logistics network
Dec 4, 2023 11:36am
Cell therapy allows kidney recipients to cut immunosuppressants
Nov 2, 2023 10:00am
CRISPR-edited pig kidney lasts for 2 years in primates
Oct 11, 2023 11:13am
Humanized kidneys grown in pig embryos for the first time
Sep 12, 2023 7:15am
FDA clears Paragonix's pressure-controlled lung transport system
Aug 25, 2023 9:32am